Biovigilance and pharmacovigilance for haemophilia

被引：6

作者：

Weinstein, M. ^{[2
]}

Makris, M. ^{[3
]}

Ludlam, C. A. ^{[1
]}

机构：

[1] Royal Infirm, Comprehens Care Haemophilia & Thrombosis Ctr, Edinburgh EH16 4SA, Midlothian, Scotland

[2] US FDA, Off Blood Res & Review, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA

[3] Univ Sheffield, Dept Haematol, Sheffield, S Yorkshire, England

来源：

HAEMOPHILIA | 2010年 / 16卷

关键词：

Biovigilance; pharmacovigilance; Haemophilia; adverse events;

D O I：

10.1111/j.1365-2516.2010.02288.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：17 / 21

页数：5

共 7 条

[1] Reconstituting factor concentrates:: Defining Evidence of Coaching Non-Experts (DEVICE) in haemophilia -: a prospective randomized feasibility study [J].

Bidlingmaier, C. ;

Kurnik, K. ;

Hoelscher, G. ;

Kappler, M. .

HAEMOPHILIA, 2007, 13 (05) :470-472

[2] Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A [J].

Chalmers, E. A. ;

Brown, S. A. ;

Keeling, D. ;

Liesner, R. ;

Richards, M. ;

Stirling, D. ;

Thomas, A. ;

Vidler, V. ;

Williams, M. D. ;

Young, D. .

HAEMOPHILIA, 2007, 13 (02) :149-155

[3]

HANIFF H, 2008, HEPARIN PRODUCTS TAR

[4]

*PUBL HLTH SER BIO, BIOV US EFF BRIDG CR

[5]

1996, MMWR WEEKLY, V45, P29

[6]

2002, BIOTECHNOLOGY LAW RE, V21, P366

[7]

1996, MMWR WEEKLY NOT 1011, V45, P866

← 1 →